Alec  Machiels net worth and biography

Alec Machiels Biography and Net Worth

Alec Machiels is the Founder and Managing Partner of CoLift, a new private equity platform bringing together a global network of leaders with bespoke investment opportunities. He was a Partner at Pegasus Capital Advisors, L.P., a private equity fund manager with approximately $2bn in assets under management. Mr. Machiels was a member of the firm’s executive and investment committees. He has over 20 years of private equity investing and investment banking experience. Previously, Mr. Machiels was a financial analyst in the Financial Services Group at Goldman Sachs International in London and in the Private Equity Group at Goldman Sachs & Co. in New York. Investments in which he has been highly involved include Pure Biofuel, Molycorp Minerals, Traxys, Slipstream Communications, Coffeyville Resources, and Merisant Company. He also co-founded and serves as a board member of Potentia Pharmaceuticals, Inc. and Apellis Pharmaceuticals, Inc. which respectively have drugs in Phase III development to treat macular degeneration and rare diseases. He also served as a member of the board of trustees of the American Federation of Arts, where he chaired the endowment committee. Mr. Machiels is a graduate of Harvard Business School, KU Leuven Law School in Belgium, and Konstanz University in Germany.

What is Alec Machiels' net worth?

The estimated net worth of Alec Machiels is at least $13.98 million as of September 18th, 2023. Mr. Machiels owns 367,420 shares of Apellis Pharmaceuticals stock worth more than $13,976,657 as of September 30th. This net worth evaluation does not reflect any other investments that Mr. Machiels may own. Additionally, Mr. Machiels receives a salary of $72,500.00 as Director at Apellis Pharmaceuticals. Learn More about Alec Machiels' net worth.

How old is Alec Machiels?

Mr. Machiels is currently 50 years old. There are 7 older executives and no younger executives at Apellis Pharmaceuticals. The oldest executive at Apellis Pharmaceuticals is Mr. James G. Chopas CPA, VP, Corp. Controller & Chief Accounting Officer, who is 57 years old. Learn More on Alec Machiels' age.

What is Alec Machiels' salary?

As the Director of Apellis Pharmaceuticals, Inc., Mr. Machiels earns $72,500.00 per year. There are 5 executives that earn more than Mr. Machiels. The highest earning executive at Apellis Pharmaceuticals is Dr. Cedric Francois M.D., Ph.D., Co-Founder, Pres, CEO & Director, who commands a salary of $1,200,000.00 per year. Learn More on Alec Machiels' salary.

How do I contact Alec Machiels?

The corporate mailing address for Mr. Machiels and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at [email protected]. Learn More on Alec Machiels' contact information.

Has Alec Machiels been buying or selling shares of Apellis Pharmaceuticals?

Over the course of the past ninety days, Alec Machiels has sold $193,912.50 in Apellis Pharmaceuticals stock. Most recently, Alec Machiels sold 1,250 shares of the business's stock in a transaction on Monday, September 18th. The shares were sold at an average price of $45.00, for a transaction totalling $56,250.00. Following the completion of the sale, the director now directly owns 367,420 shares of the company's stock, valued at $16,533,900. Learn More on Alec Machiels' trading history.

Who are Apellis Pharmaceuticals' active insiders?

Apellis Pharmaceuticals' insider roster includes Victoria Brown (Insider), James Chopas (CAO), Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Jeffrey Eisele (Insider), Cedric Francois (CEO), Federico Grossi (Insider), Karen Lewis (Insider), Alec Machiels (Director), Nur Nicholson (Insider), Nicole Perry (VP), Lukas Scheibler (Insider), Timothy Sullivan (CFO), Adam Townsend (Insider), and David Watson (General Counsel). Learn More on Apellis Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Apellis Pharmaceuticals?

During the last twelve months, insiders at the sold shares 48 times. They sold a total of 580,153 shares worth more than $35,795,305.80. The most recent insider tranaction occured on September, 18th when Director Alec Machiels sold 1,250 shares worth more than $56,250.00. Insiders at Apellis Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Apellis Pharmaceuticals.

Information on this page was last updated on 9/18/2023.

Alec Machiels Insider Trading History at Apellis Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/18/2023Sell1,250$45.00$56,250.00367,420View SEC Filing Icon  
9/15/2023Sell1,250$45.34$56,675.00367,420View SEC Filing Icon  
7/17/2023Sell1,250$64.79$80,987.50267,641View SEC Filing Icon  
6/20/2023Sell1,250$88.41$110,512.50267,641View SEC Filing Icon  
5/17/2023Sell1,250$88.66$110,825.00267,641View SEC Filing Icon  
4/17/2023Sell1,250$81.05$101,312.50267,641View SEC Filing Icon  
3/17/2023Sell1,250$64.03$80,037.50267,641View SEC Filing Icon  
1/17/2023Sell1,250$52.42$65,525.00267,641View SEC Filing Icon  
12/15/2022Sell1,250$52.35$65,437.50263,774View SEC Filing Icon  
10/14/2022Sell1,250$59.31$74,137.50263,774View SEC Filing Icon  
9/15/2022Sell1,250$66.00$82,500.00263,774View SEC Filing Icon  
8/15/2022Sell1,250$67.21$84,012.50263,774View SEC Filing Icon  
7/15/2022Sell1,250$46.33$57,912.50263,774View SEC Filing Icon  
6/15/2022Sell1,250$39.29$49,112.50263,774View SEC Filing Icon  
5/16/2022Sell1,250$39.18$48,975.00263,774View SEC Filing Icon  
4/14/2022Sell1,250$50.90$63,625.00263,774View SEC Filing Icon  
3/15/2022Sell1,250$39.57$49,462.50View SEC Filing Icon  
2/15/2022Sell1,250$45.43$56,787.50View SEC Filing Icon  
1/14/2022Sell1,250$40.56$50,700.00View SEC Filing Icon  
7/15/2021Sell2,500$62.30$155,750.00672,044View SEC Filing Icon  
6/15/2021Sell2,500$64.83$162,075.00672,044View SEC Filing Icon  
4/21/2021Sell2,500$45.76$114,400.00672,044View SEC Filing Icon  
3/15/2021Sell2,500$46.77$116,925.00672,044View SEC Filing Icon  
1/15/2021Sell2,500$53.15$132,875.00672,044View SEC Filing Icon  
11/16/2020Sell2,500$39.38$98,450.00672,044View SEC Filing Icon  
10/15/2020Sell2,500$35.00$87,500.00672,044View SEC Filing Icon  
10/7/2020Sell7,500$35.00$262,500.00677,044View SEC Filing Icon  
See Full Table

Alec Machiels Buying and Selling Activity at Apellis Pharmaceuticals

This chart shows Alec Machiels's buying and selling at Apellis Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals logo
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $38.04
Low: $37.93
High: $40.42

50 Day Range

MA: $36.60
Low: $23.65
High: $48.53

2 Week Range

Now: $38.04
Low: $19.83
High: $94.75


1,859,064 shs

Average Volume

2,663,248 shs

Market Capitalization

$4.48 billion

P/E Ratio


Dividend Yield